$SMMT News Article - Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole's Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
https://marketwirenews.com/news-releases/summ...15099.html